Contributions
Abstract: PB1455
Type: Publication Only
Session title: Aggressive Non-Hodgkin lymphoma - Clinical
Background
Mature T / NK cell lymphoma account for 10 to 20% of all malignant lymphomas, and their treatment results are poor compared to B-cell lymphomas. The standard treatment is CHOP therapy, but the therapeutic effect is not sufficient. Here, we examined the treatment results of mature T / NK cell lymphoma in our institution.
Aims
To characterize treatment patterns and outcome for newly diagnosed mature T / NK cell lymphoma patients.
Methods
We retrospectively analyzed 123 cases of mature T / NK cell lymphoma who visited our institution from April 2007 to December 2017 based on medical records.
Results
81 men and 42 women, with median age 68, range 31-90 years. Diagnosis was PTCL-NOS 34 (27.6%), AILT 24 (19.5%), ENKL 23 (18.7%), ALCL 15 (12.2%), ATL 17 (13.8%), MEITL 6 (4.9%) and others 4 (3.3%). Clinical stage I-II 39 (31.7%), extranodal involvement 93 (75.3%), B symptoms 21 (17.7%), bone marrow infiltration 21 (17.1%). Chemotherapy was performed in 109 (88.6%), CHOP 52 (47.7%), CyclOBEAP 17 (15.6%), and 2/3 DeVIC + radiotherapy 14 (12.8%). 9 (7.3%) received only palliative care. The median observation period was 17 months, and the 3-year OS and PFS were 51.6% and 40.2%, and the 3-year PFS of chemotherapy patients was 46.8%. By histological subtype, ALCL ALK+ 100%, ALCL ALK- 66.7%, ENKL 46.5%, AILT 39.7%, PTCL 34.2%, ATL 22.5%, MEITL 0%. By multivariate analysis, PIT, response to initial therapy and MEITL were associated with PFS(P=0.011, P<0.001, P=0.006). PIT, response to initial therapy and Age was associated with OS (P=0.011, P<0.001,P=0.009 ).
Conclusion
Mature T / NK cell lymphoma generally have a poorer prognosis than DLBCL, but the prognosis differs depending on the histological subtype, and it is important to determine a stratified treatment policy in the future.
Keyword(s): Peripheral T-cell lymphoma
Abstract: PB1455
Type: Publication Only
Session title: Aggressive Non-Hodgkin lymphoma - Clinical
Background
Mature T / NK cell lymphoma account for 10 to 20% of all malignant lymphomas, and their treatment results are poor compared to B-cell lymphomas. The standard treatment is CHOP therapy, but the therapeutic effect is not sufficient. Here, we examined the treatment results of mature T / NK cell lymphoma in our institution.
Aims
To characterize treatment patterns and outcome for newly diagnosed mature T / NK cell lymphoma patients.
Methods
We retrospectively analyzed 123 cases of mature T / NK cell lymphoma who visited our institution from April 2007 to December 2017 based on medical records.
Results
81 men and 42 women, with median age 68, range 31-90 years. Diagnosis was PTCL-NOS 34 (27.6%), AILT 24 (19.5%), ENKL 23 (18.7%), ALCL 15 (12.2%), ATL 17 (13.8%), MEITL 6 (4.9%) and others 4 (3.3%). Clinical stage I-II 39 (31.7%), extranodal involvement 93 (75.3%), B symptoms 21 (17.7%), bone marrow infiltration 21 (17.1%). Chemotherapy was performed in 109 (88.6%), CHOP 52 (47.7%), CyclOBEAP 17 (15.6%), and 2/3 DeVIC + radiotherapy 14 (12.8%). 9 (7.3%) received only palliative care. The median observation period was 17 months, and the 3-year OS and PFS were 51.6% and 40.2%, and the 3-year PFS of chemotherapy patients was 46.8%. By histological subtype, ALCL ALK+ 100%, ALCL ALK- 66.7%, ENKL 46.5%, AILT 39.7%, PTCL 34.2%, ATL 22.5%, MEITL 0%. By multivariate analysis, PIT, response to initial therapy and MEITL were associated with PFS(P=0.011, P<0.001, P=0.006). PIT, response to initial therapy and Age was associated with OS (P=0.011, P<0.001,P=0.009 ).
Conclusion
Mature T / NK cell lymphoma generally have a poorer prognosis than DLBCL, but the prognosis differs depending on the histological subtype, and it is important to determine a stratified treatment policy in the future.
Keyword(s): Peripheral T-cell lymphoma